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Background: Epidemiological studies have shown that chronic kidney disease (CKD) is an important risk factor for
atherosclerosis and cardiovascular disease (CAD). The aim of the study was to determine markers of increased risk
of CAD and to achieve a better understanding of agents implicated in the process of atherosclerosis in CKD
patients.
Methods: The study group consisted of a total of 139 patients with CKD while the control group comprised 45
healthy volunteers. Concentrations of osteoprotegerin, osteopontin, osteocalcin, matrix γ-carboxyglutamic acid
(Gla) protein (MGP), fetuin A, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), tissue inhibitor
of metalloproteinase-1 (TIMP-1), tissue inhibitor of metalloproteinase-2 (TIMP-2), ATP binding cassette transporter A1
(ABCA1), ATP binding cassette transporter G1 (ABCG1) and renalase were measured by the ELISA method.
Results: We observed decreased levels of fetuin A (control vs. CKD group: 37.5 vs. 33.2 ng/ml, p = 0.018), and increased
concentrations of osteocalcin (control vs. CKD group: 9.1 ± 6.0 vs. 13.6 ± 10.3 ng/ml, p = 0.05), MMP-2 (113.1 ± 75.0 vs.
166.0 ± 129.9 ng/ml, p = 0.045), TIMP-2 (22.1 ± 5.1 vs. 25.4 ± 7,0 ng/ml, p = 0.005) and renalase (251.0 ± 157 vs. 316.1 ±
155.3 ng/ml, p = 0.026). In patients with CKD (in comparison to control group), left ventricle ejection fraction: 53.0 ±
3,5% vs. 48.5%, p = 0.012) and calcification of the aortic valve (9.5% vs. 39.8%, p = 0.008) were observed more frequently.
Conclusions: Decreased levels of fetuin A and increased concentration of osteocalcin, renalase, MMP-2 and TIMP-2
suggest that these factors may be involved in the pathogenesis of CAD in patients with CKD. Significantly increased
indices of cardiac hypertrophy and its dysfunction in patients with CKD are indicators of pathological mechanisms
occurring in cardiovascular system in this group of patients.
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Chronic kidney disease (CKD) is a significant clinical
problem worldwide, with constantly increasing inci-
dence. Epidemiological studies have shown that chronic
kidney disease is an important risk factor for cardiovas-
cular disease [1]. Increased coronary artery disease
(CAD) risk is associated with increased atherosclerosis,
which is more frequent in patients with CKD, especially
the dialysis ones, than in the general population. Car-
diovascular disease is also the most common cause of
mortality in this group of patients [2-4]. According to* Correspondence: aniagluba@yahoo.pl
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article, unless otherwise stated.Foley et al. [3], the cardiovascular mortality rate in end
stage renal disease (ESRD) patients is 10–20 times higher
than in the general population after stratification for age,
race and gender. At the time of starting renal replacement
therapy, the prevalence of CAD is even higher [5-7]. The
Hemodialysis (HEMO) Study revealed that ischaemic
heart diseases (20.4%) as well as cardiac rhythm disorder
(10.4%) were the most common cause of death in dia-
lysed patient [8]. Increased risk of atherosclerosis in
these patients is due to the overlapping of traditional
risk factors of atherosclerosis with CKD-specific factors
(i.e. altered calcium and phosphorus homeostasis, mal-
nutrition, anaemia, hyperhomocysteinaemia, low serum
albumin and high fibrinogen levels, as well as oxidative
stress and inflammatory state) that further exacerbateCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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[9,10]. So far, plaque formation mechanisms in this group
of patients are not known, because patients with CKD were
often excluded from the study. It seems that greater severity
of atherosclerosis in patients with CKD may be associated
with impaired lipid and calcium phosphate metabolism.
Moreover, arterial calcification, which is an independent
risk factor for acute coronary events, is observed even in
young patients with CKD. Numerous studies have shown
that bone metabolism plays an important role in patients
with chronic kidney disease. Osteopontin, osteoprotegerin,
fetuin A and matrix γ-carboxyglutamic acid protein (MGP)
are the most important factors in the inhibition of calcifi-
cations. Additionally, matrix metalloproteinases (MMPs),
which are involved in tissue remodelling, are implicated in
the pathogenesis of both cardiovascular disease and kid-
ney disease. Studies have shown that MMP-2, MMP-9
and tissue inhibitors of metalloproteinase −1 (TIMP-1)
and −2 (TIMP-2) also play an important role in the patho-
genesis of renal damage [11,12].
The aim of the study was to determine markers of in-
creased risk of CAD occurring in CKD patients and to
achieve a better understanding of agents implicated in
plaque formation in this group of patients. The study
may support the identification of individuals who are at
high risk of cardiovascular events in order to implement
early prevention.
Methods
The study group consisted of a total of 139 patients with
CKD (30 patients with stage I/II CKD, 30 stage III CKD,
30 stage IV CKD and 49 stage V/dialysis) hospitalized in
the Department of Nephrology, Hypertension and Family
Medicine. The control group consisted of 45 healthy vol-
unteers recruited from patients hospitalized due to causes
other than CKD, CAD, hypertension, or diabetes mellitus.
All subjects enrolled in this study were informed about
its purpose and methodology and signed an informed
consent form. The study was approved by the Bioethics
Committee of the Medical University of Lodz (no. RNN/
79/12/KB). The levels of studied proteins and biochemical
markers were analysed in blood of all people involved in
the study. The study excluded patients with diagnosed
cancer, autoimmune diseases and those with a history of
myocardial infarction. In the present study, concentrations
of proteins involved in the processes of vessel wall cal-
cification and bone metabolism disorders (osteoproteg-
erin [TECOMedical, no. 8034], osteopontin [RayBiotech,
ELH-OPN-001], osteocalcin [TECOMedical, no. 8002],
matrix γ-carboxyglutamic acid protein (MGP) [USCN Life
Science, E91477Hu], fetuin A [TECOMedical, no. KT-800]),
vascular remodelling (MMP-2, MMP-9, TIMP-1, TIMP-2
[Raybiotech: ELH-MMP2-001, ELH-MMP9-001, ELH-
TIMP1-001, ELH-TIMP2-001]), cholesterol transport (ATP-binding cassette transporters ABCA1 [Uscn Life Science Inc.,
E91242Hu], ABCG1 [Uscn Life Science Inc., E91288Hu])
as well as renalase [USCN Life Science, E92845Hu] were
measured in order to analyse their influence on cardiovas-
cular risk in CKD patients. Levels of these proteins were
determined by the ELISA method according to the manu-
facturer’s instructions.
Levels of biochemical markers such as total cholesterol,
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triglyceride (TG), albuminuria, serum calcium and
phosphate, Fe, total iron-binding capacity (TIBC), C-
reactive protein (CRP), alkaline phosphatase activity, cre-
atinine, urea, uric acid, total protein, the level of fibrinogen
and D-dimers were also determined. Estimated glomerular
filtration rate (GFR-MDRD) was calculated using the
Modification of Diet in Renal Disease:
GFR ml=min=1:73 m2
  ¼ 186 Creat=88:4ð Þ‐1:154
 Ageð Þ‐0:203
 0:742 if femaleð Þ
 1:210 if blackð Þ:
In addition, cardiac echocardiography was performed
to assess heart condition and function, the presence of
left ventricular hypertrophy and systolic and diastolic
function disturbances. The following cardiac indexes were
measured: end-systolic interventricular septum thickness
(IVSs), end-diastolic interventricular septum thickness
(IVSd), left ventricle mass (LV mass), diameter of the left
ventricle during systole (LVsys) and diastole (LVdias), left
atrial (LA) size, right ventricle (RV) size, aorta, mitral
insufficiency (IM), aortic insufficiency (IA), tricuspid in-
sufficiency (IT), early (E) to late (A) ventricular filling vel-
ocities ratio (E/A), early transmitral velocity (E’), ratio of
early transmitral velocity to mitral annular early diastolic
velocity (E/E’), deceleration time (DT), ejection fraction
(EF%), valve calcification/fibrosis.
Statistical analysis
Results were expressed as mean with standard deviation
(mean ± SD) for continuous variables with normal distri-
bution or as median with interquartile range (median,
25%-75%) in all other cases. The Shapiro-Wilk test was
used to verify normal distribution of variables and Levene
test to analyse the homogeneity of variance. Standard
Student t test for the comparison of data showing no
departures from normality, and the non-parametric
Mann–Whitney U test for the remaining variables were
used. For detailed multiple comparisons (more than two
groups) one-way ANOVA with post hoc Tukey tests or
non-parametric analysis of variance (Kruskal-Wallis test)
with post hoc Conover-Inman tests was used, respectively.
The χ2 test of independence was used for the analysis of
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Results
The characteristics of studied groups
The average age of patients in the study group (all CKD
stages) was 67.1 ± 12.9 years and 59.4 ± 10.0 in the con-
trol group. Men were in the majority in the study groups
while women were in the majority in the control group.
Diabetes, hypertension, atrial fibrillation, general athero-
sclerosis and CRP > normal level occurred much more
often in the study group than in controls. eGFR-MDRD
was also much higher in the control group compared to
study group, which is not surprising. No significant dif-
ferences in the prevalence of obesity and lipid disorders
were observed between groups. Demographic data are
summarized in Table 1.
The analysis of biochemical parameters
The analysis of biochemical parameters and echocardio-
graphic indices in study group and controls was also
performed (results are summarized in Table 1). Statisti-
cally significant differences in the level of K+, haemoglobin,
APTT, Fe, LDL, total cholesterol, inorganic phosphate and
calcium ions between control and study group were ob-
served. These differences were also noticeable between pa-
tients with various CKD stages. Moreover, in CKD patients
markers of kidney damage (urea, creatinine, albumin and
uric acid) were significantly higher than in controls.
The analysis of echocardiographic indices
Echocardiographic examination revealed that patients
with CKD in comparison with the control group had sig-
nificantly greater interventricular septal end diastolic di-
mension, higher left ventricular mass and much larger
systolic and diastolic dimensions of the left ventricle, in-
dicating pathological cardiac hypertrophy. These patients
also had a significantly greater left atrial dimension.
Chronic kidney disease patients were also more likely to
have aortic valve calcification and their ejection fraction
was significantly lower than in the control group. These
observations confirm the adverse effect of renal disease
on the cardiovascular system. Although diastolic dys-
function is frequent in patients with CKD, there were no
significant differences in its indices, such as E/A and E/E’
between study and control group.
The analysis of proteins concentrations
Analysis of the concentrations of proteins associated
with bone metabolism revealed no statistically significant
differences in the level of osteoprotegerin, osteopontin,
or MPG between the control group and patients with
chronic kidney disease (all stages). However, it was ob-
served that the concentration of fetuin A in study groupwas significantly lower than in controls (33.2 vs. 37.5 ng/ml,
p = 0.018) while the level of osteocalcin was significantly
higher in patients with CKD (13.6 ± 10.3 vs. 9.1 ± 6.0 ng/ml,
p = 0.05). Moreover, differences in fetuin A, osteocalcin
and osteoprotegerin between groups of patients in various
CKD stages were seen. Fetuin A level was highest in
patients with mild kidney disease and lowest in dialy-
sis patients (p = 0.002); osteocalcin and osteoprotegerin
concentrations were highest in dialysis patients and lowest
in stages I/II (p < 0.0001 and p = 0.005, respectively). The
results are summarized in Table 1. The study of matrix
metalloproteinases and their inhibitors revealed that the
level of MMP-2 was much higher in patients with chronic
kidney disease in comparison to the control group (p =
0.045) and that statistically significant differences between
various stages of CKD were also present (p = 0.008). Its
highest values were seen in patients with mild kidney dis-
ease (stage I/II) then it gradually decreased to reach the
lowest value in patients with stage V/dialysis. In case of
MMP-9 level only a slight tendency to increase with the
worsening of kidney function was noted. Significant differ-
ences in proteins concentration between study and control
groups were also observed in case of metalloproteinase in-
hibitor TIMP-2 (p = 0.005) and in the level of TIMP-1 and
TIMP-2 between various CKD stages (p = 0.048 and p =
0.003, respectively). The highest concentrations of TIMP-1
and TIMP-2 were observed in end-stage renal disease pa-
tients and the lowest in I/II CKD patients. Furthermore, it
was noted that the ratio MMP-2/TIMP-2 was significantly
lower in V/dialysis patients than in patients with mild
renal impairment (p = 0.001). The level of renalase also
differed significantly between CKD patients and control
group (p = 0.026) and between patients with various CKD
stages (p < 0.0001).
The analysis of relationship between protein concentration
and biochemical parameters
The analysis of the relationship between the incidence of
both calcification and fibrosis and sex (male), age, level of
calcium ions and inorganic phosphate in plasma demon-
strated that the risk of mitral valve fibrosis is increased
every year 1.15-fold, the risk of aortic valve fibrosis 1.02-
fold and the risk of mitral valve calcification by 1.05, re-
gardless of the concentration of Ca2+, inorganic phosphate
level and sex. The results are shown in Table 2.
An analysis of the relationship between concentrations
of studied proteins and biochemical parameters was also
performed. In the present study an association between
serum osteocalcin, osteoprotegerin and fetuin A and the
level of inorganic phosphate and between osteoprotegerin
levels and CRP was found. Moreover, there was a relation-
ship between fetuin A concentration and the level of cal-
cium ions. In the present study, no association was
observed between the concentration of transport proteins
Table 1 Detailed characteristics of included patients
Control group N = 45 CKD all stages N = 132 p Stage I/II N = 30 Stage III N = 30 Stage IV N = 30 Stage V N = 49 p
Age 59.4 ± 10.0 67.1 ± 12.9 P < 0.0001 69.0 ± 10.71 64.5 ± 14.8 67.9 ± 14.4 67.3 ± 12.11 P = 0.005
Sex, male (%) 35.6% 56.1% P = 0.017 51.9% 51.6% 36.0% (71.4)3 P = 0.0053
DM (%) 11.1% 34.1% P = 0.003 22.2% 32.31 24.0% 46.93 P = 0.003
Hypertension (%) 48.9% 88.6% P < 0.0001 92.6%3 90.3%3 92.0%3 83.7%3 P < 0.0001
Lipid disorders (%) 37.8% 31.1% NS 25.9% 38.7% 40.0% 24.5% NS
Obesity (%) 33.3% 37.1% NS 51.9% 45.2% 32.0% 26.5% NS
General atherosclerosis (%) 6.7% 25.0% P = 0.008 25.9% 16.1% 24.0% 30.6%2 P = 0.05
K+ [mmol/l] 4.27 ± 0.52 4.64 ± 0.73 P = 0.007 4.59 ± 0.56 4.31 ± 0.48 4.62 ± 0.58 4.9 ± 0.92,7 P = 0.003
Haemoglobin [g/dl] 13.4 ± 1.5 11.3 ± 2.0 P < 0.0001 11.9 ± 1.81 12.6 ± 1.8 11.2 ± 2.03 10.2 ± 1.63,5,9 P < 0.0001
Platelet [*103/μl] 246.3 ± 70.6 244.1 ± 95.3 NS 250.4 ± 108.6 243.2 ± 71.4 250.0 ± 120.2 238.0 ± 89.1 NS
Monocytes [*103/μl] 0.44 ± 0.14 0.49 ± 0.23 NS 0.49 ± 0.21 0.50 ± 0.25 0.57 ± 0.29 0.46 ± 0.19 NS
CRP [mg/l] 1.7 (0.8-4.8) 6.4 (2.3-12.4) P < 0.0001 6.4 (2.0-12.7)1 3.9 (1.9-7.9) 7.6 (2.4-18.1)2 7.9 (3.4-17.1)3 P < 0.0001
ALP [U/l] 82.2 ± 34.9 94.5 ± 55.4 NS 93.3 ± 32.8 69.2 ± 31.7 111.8 ± 101.9 100.8 ± 40.18 P = 0.004
79.5 (59.2-97.0) 86.0 (66.0-108.2) 88.5 (66.7-106.6) 67.0 (51.0-82.0) 82.0 (66.0-107.0) 97.0 (73.5-117.0)
APTT [s] 29.4 ± 3.1 37.4 ± 11.4 P < 0.0001 34.2 ± 5.11 35.5 ± 12.4 40.0 ± 14.82 38.2 ± 10.43 P < 0.0001
APTT ratio 0.95 ± 0.21 1.13 ± 0.37 P = 0.002 1.06 ± 0.19 1.10 ± 0.45 1.16 ± 0.43 1.14 ± 0.342 P = 0.019
Fe [μmol/l] 16.9 ± 6.0 11.5 ± 6.2 P < 0.0001 10.5 ± 5.72 15.3 ± 8.1 11.0 ± 4.62 10.4 ± 5.53,7 P < 0.0001
TIBC [μmol/l] 49.0 (45.0-50.0) 44.6 (36.5-56.8) NS 54.2 (35.7-61.0) 61.0 (52.5-145.5) 45.0 (36.5-57.1)7 39.9 (34.7-47.6)3 P < 0.0001
Ferritin [ng/ml] 271.0 (8.5-328.0) 228 (105.5-680.5) NS 182.5 (66.0-421.2) 134.9 (49.0-221.0) 277 (153.3-868.0) 444 (137.0-844.0) NS (P = 0.097)
Ca2+ [mmol/l] 2.36 ± 0.11 2.24 ± 0.23 P = 0.006 2.25 ± 0.20 2.34 ± 0.20 2.30 ± 0.21 2.15 ± 0.243,9,10 P < 0.0001
Inorganic P [mmol/l] 1.12 ± 0.15 1.49 ± 0.49 P < 0.0001 1.49 ± 0.66 1.23 ± 0.24 1.39 ± 0.361 1.67 ± 0.483,8 P < 0.0001
LDL [mmol/l] 3.50 ± 0.76 3.08 ± 1.66 P = 0.001 2.96 ± 1.08 3.25 ± 1.68 3.86 ± 2.77 2.69 ± 1.012 P = 0.007
HDL [mmol/l] 1.34 ± 0.36 1.26 ± 0.44 NS 1.37 ± 0.42 1.21 ± 0.38 1.38 ± 0.58 1.16 ± 0.39 NS (P = 0.077)
TG [mmol/l] 1.6 ± 1.0 1.91 ± 1.00 NS (0.063) 1.7 ± 0.7 2.3 ± 1.3 1.8 ± 1.0 1.8 ± 0.9 NS
Total cholesterol [mmol/l] 5.35 ± 0.79 5.13 ± 2.12 P = 0.033 5.05 ± 1.14 5.29 ± 1.72 6.08 ± 3.81 @4.54 ± 1.20 P = 0.035
Albumin [g/l] 44.8 ± 4.6 38.6 ± 6.1 P < 0.0001 38.1 ± 6.61 39.5 ± 6.8 39.4 ± 6.1 37.9 ± 5.53 P = 0.002
Urea [mmol/l] 5.7 ± 2.0 17.1 ± 10.3 P < 0.0001 14.1 ± 8.53 13.0 ± 12.82 17.5 ± 7.23 21.2 ± 9.63,9 P < 0.0001
5.1 (4.5-6.4) 15.5 (9.1-22.5) 11.5 (7.0-24.2) 9.8 (6.7-13.5) 17.0 (11.7-21.7) 20.6 (15.8-25.3)
Creatinine [μmol/l] 83.1 ± 14.5 330.1 ± 234.9 P < 0.0001 290.6 ± 247.73 159.6 ± 81.83 260.2 ± 139.53 502.5 ± 228.25,9 P < 0.0001
82.0 (75.0-92.0) 264 (131.7-470.5) 227 (109–415) 137 (113–174) 232 (172.5-300) 497 (329–677)3
Total protein [g/l] 69.5 ± 3.9 66.8 ± 10.0 NS 69.2 ± 10.5 63.7 ± 9.9 70.7 ± 9.8 65.4 ± 9.2 NS (P = 0.084)
Uric acid [μmol/l] 305.0 ± 83.9 416.2 ± 128.3 P < 0.0001 442.8 ± 122.83 418.3 ± 117.72 459.8 ± 134.73 375.7 ± 126.5 P < 0.0001






















Table 1 Detailed characteristics of included patients (Continued)
IVsd [mm] 13.6 ± 1.9 15.0 ± 2.6 P = 0.009 14.1 ± 1.8 14.7 ± 2.5 14.1 ± 2.1 16.3 ± 2.93,4,10 P < 0.0001
IVss [mm] 15.1 ± 1.4 15.5 ± 2.1 NS 16.0 ± 2.1 15.4 ± 1.9 15.0 ± 2.2 15.5 ± 2.2 NS
LV mass [g] 234.4 ± 51.1 345.0 ± 126.8 P < 0.0001 293.2 ± 72.5 326.8 ± 117.5 310.1 ± 96.0 403.5 ± 148.73,5,10 P < 0.0001
LV hypertrophy [%] 95.2(%) 94.2% NS 92.3% 96.6% 90.0% 95.6% NS
LV sys [mm] 37.1 ± 4.1 40.7 ± 7.6 P = 0.045 38.5 ± 5.7 39.9 ± 5.7 38.7 ± 6.3 43.2 ± 9.51 P = 0.035
LV dias [mm] 44.1 ± 7.0 48.7 ± 7.2 P = 0.007 46.0 ± 5.0 47.4 ± 6.4 47.7 ± 5.7 51.5 ± 8.52 P = 0.003
LA [mm] 40.6 ± 2.9 42.4 ± 4.1 P = 0.036 41.3 ± 2.9 41.2 ± 3.9 41.7 ± 3.2 44.2 ± 4.62,4,8 P < 0.0001
RV [mm] 26.0 ± 3.3 27.5 ± 3.8 NS 27.6 ± 2.1 26.8 ± 4.7 26.9 ± 3.8 28.1 ± 3.8 NS
E/A 0.87 ± 0.27 1.09 ± 0.59 NS 1.09 ± 0.73 0.80 ± 0.17 1.14 ± 0.187 1.21 ± 0.66 P = 0.014
E/E’ 7.9 ± 1.7 10.7 ± 4.8 NS 8.6 ± 4.2 8.8 ± 4.1 12.6 ± 4.6 12.3 ± 4.9 NS
Dec (DT) 209.6 ± 56.2 270.6 ± 123.6 NS 301.5 ± 157.9 321.3 ± 132.8 213.2 ± 73.4 246.6 ± 98.2 NS
Contractility disorders [%] 52.4% 62.2% NS 36.8% 45.0% 43.8% 88.4%2,6,9,11 P = 0.0001
EF% 53.0 ± 3.5 48.5 ± 8.6 P = 0.012 50.8 ± 4.5 51.1 ± 8.4 49.9 ± 10.2 45.5 ± 8.97 P = 0.001
Mitral valve fibrosis [%] 63.6% 82.4% NS (P = 0.079) 87.0% 73.9% 70.6% 88.9% NS
Aortic valve fibrosis [%] 13.6% 12.0% NS 8.7% 8.7% 11.8% 15.6% NS
Mitral valve calcification [%] 9.1% 21.3% NS 8.7% 13.0% 11.8% 15.6% NS
Aortic valve calcification [%] 9.5% 39.8% P = 0.008 26.1% 21.7% 23.5% 35.6% NS
IM [%] 63.6% 71.6% NS 65.2% 54.2% 64.7% 86.7%2 P = 0.045
IA [%] 4.8% 12.8% NS 13.0% 8.3% 5.9% 17.8% NS
IT [%] 36.4% 58.3% NS (P = 0.059) 47.8% 43.5% 47.1% 75.6%2,4,7 P = 0.012
Fetuin A [ng/ml] 37.5 (31.6-126.6) 33.2 (27.5-89.4) P = 0.018 70.6 (30.9-119.7) 34.1 (28.5-92.5) 31.4 (26.2-114.0) 29.8 (25.5-37.5)2,4 P = 0.002
Osteocalcin [ng/ml] 9.1 ± 6.0 13.6 ± 10.3 P = 0.05 10.6 ± 9.0 8.4 ± 5.8 11.7 ± 9.8 19.2 ± 11.13,4,9 P < 0.0001
8.2 (5.1-13.0) 10.5 (5.0-23.1) 6.7 (4.3-19.1) 7.6 (4.3-11.9) 9.2 (4.5-17.9) 22.9 (8.5-28.2)
Osteopontin [ng/ml] 8.8 (7.2-37.8) 9.3 (7.8-17.8) NS 9.4 (6.7-20.9) 8.1 (7.4-16.1) 9.8 (8.1-25.2) 9.3 (8.0-13.8) NS
Osteoprotegerin [pmol/l] 7.6 ± 5.5 8.5 ± 6.2 NS 7.5 ± 6.9 5.8 ± 4.6 8.2 ± 6.0 10.8 ± 6.22 P = 0.005
5.7 (2.9-12.0) 7.4 (3.5-12.2) 7.2 (1.1-11.0) 5.2 (1.1-9.5) 6.3 (3.7-11.6) 10.1 (6.1-14.4)
MGP [ng/ml] 92.9 ± 28.5 86.7 ± 36.7 NS 77.1 ± 43.5 83.1 ± 33.9 89.5 ± 32.1 92.6 ± 36.7 NS
ABCG1 [ng/ml] 2.25 (0.98-2.58) 1.93 (0.72-2.43) NS 1.94 (1.64-2.34) 1.86 (0.59-2.36) 2.19 (0.89-2.63) 1.84 (0.46-2.49) NS
ABCA1 [ng/ml] 0.70 (0.62-0.75) 0.60 (0.44-0.74) NS (P = 0.079) 0.71 (0.55-0.88) 0.51 (0.41-0.71) 0.59 (0.42-1.02) 0.58 (0.30-0.71) NS (P = 0.054)
MMP-2 [ng/ml] 94.8 (54.2-166.3) 129.9 (73.4-219.3) P = 0.045 206.9 ± 142.7 202.5 ± 152.3 160.6 ± 130.0 130.7 ± 105.8 P = 0.008
113.1 ± 75.0 166.0 ± 129.9 166.9 (86.4-304.5)1 156.1 (105.7-274.2)1 136.5 (70.6-225.1) 103.4 (63.4-160.1)
MMP-9 [ng/ml] 21.5 ± 6.4 22.5 ± 7.1 NS 20.1 ± 7.4 21.9 ± 6.2 22.7 ± 8.0 23.9 ± 6.9 NS






















Table 1 Detailed characteristics of included patients (Continued)
TIMP-2 [ng/ml] 22.1 ± 5.1 25.4 ± 7.0 P = 0.005 23.5 ± 6.4 23.9 ± 5.5 25.3 ± 6.5 27.3 ± 8.02 P = 0.003
MMP-2/TIMP-2 4.5 (2.5-7.9) 6.1 (3.0-11.4) NS (P = 0.056) 11.0 (5.7-17.9)2 7.4 (4.4-14.7) 6.3 (3.3-11.4) 3.8 (2.0-8.4)5 P = 0.001
MMP-9/TIMP-1 1.09 (0.65-1.28) 1.15 (0.75-1.37) NS 1.16 ± 0.56 1.17 ± 0.71 1.08 ± 0.41 1.11 ± 0.37 NS
Renalase [ng/ml] 251.0 ± 157.0 316.1 ± 155.3 P = 0.026 354.5 ± 181.6 235.3 ± 152.3 279.4 ± 162.2 369.0 ± 110.52,5 P < 0.0001
1vs control, p < 0.05; 2vs control, p < 0.01; 3vs control, p < 0.001.
4vs stage I-II, p < 0.05; 5vs stage I-II, p < 0.01; 6vs stage I-II, P < 0.001.
7vs stage III, p < 0.05; 8vs stage III, p < 0.01; 9vs stage III, p < 0.001.






















Table 2 Correlation between the presence of fibrosis and calcification and selected parameters
Sex (male) Age Ca2+ Inorganic phosphate
Mitral valve fibrosis 1.39 (0.36-5.28) NS 1.15 (1.07-1.24) P < 0.0001 0.98 (0.06-16.94) NS 3.1 (0.56-17.19) NS
Aortic valve fibrosis 0.33 (0.09-1.22) NS 1.02 (0.97-1.08) P < 0.0001 0.53 (0.04-7.51) NS 1.13 (0.36-3.47) NS
Mitral valve calcification 1.64 (0.59-4.51) NS 1.05 (1.00-1.09) P = 0.037 0.25 (0.02-2.41) NS 0.84 (0.30-2.34) NS
Aortic valve calcification 1.61 (0.65-3.97) NS 1.04 (1.00-1.08) P = 0.054 0.86 (0.11-6.82) NS 4.37 (1.57-12.15) P = 0.005
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cholesterol and triglycerides levels. There was also no rela-
tionship between the level of these proteins and a marker
of inflammation (CRP) or a marker of renal injury (cre-
atinine). A weak association was observed between the
concentration of metalloproteinase-9 and the level of CRP
(p = 0.066) and a stronger one between TIMP-2 and
MDRD-GFR (p = 0.007). The concentration of TIMP-2
also correlated with the level of iron (p = 0.018). In this
study, a relationship between the concentration of rena-
lase and the kidney injury markers creatinine and urea
was noted.
Statistically significant results of the correlation ana-
lysis are presented in Table 3.
Discussion
Biochemical and physiological abnormalities in chronic
kidney disease are associated with the attempts of the
human body to maintain homeostasis despite progres-
sive loss of nephrons and impaired kidney function.
Multiple adaptive and maladaptive processes occurring
at that time affect mainly the cardiovascular, neuro-
logical, haematological, musculoskeletal, and immuno-
logical systems [13,14].
This preliminary study analysed the possible markers
of increased cardiovascular risk and calcification pro-
cesses occurring in CKD patients.
The results of analysis of biochemical parameters –
significantly higher levels of K+, lower haemoglobin and
iron, as well as higher levels of CRP, inorganic P and tri-
glycerides in patients with CKD stages I-V in compari-
son with the control group – are consistent with the
results of other studies [15,16] and are related to kidney
damage. Decreased levels of haemoglobin are not sur-
prising since CKD patients frequently suffer from an-
aemia. The main factors leading to the development of
anaemia in this group of patients are blood loss, short-
ened red cell life span, vitamin deficiency, the ‘uremic
milieu’, iron and erythropoietin (EPO) deficiency as well
as reduced ability to bind Fe, inflammation and hyper-
parathyroidism [13]. The presence of the inflammatory
state in CKD patients is confirmed by high CRP levels.
Significantly higher concentrations of urea, creatinine
and uric acid in patients with CKD stages I-V are not as-
tonishing, since these are well-known markers of kidney
damage. In CKD patients iron homeostasis is altered.The level of transferrin is decreased, which negatively
affects the capacity of the iron-transporting system, and
the release of iron stored in macrophages and hepato-
cytes is complicated [13,17]. It is believed that lipid
abnormalities are a common phenomenon in patients
with kidney disease. In the early stages of kidney disease
the lipid profile may remain in the normal range, but
with the progression of CKD hypertriglyceridaemia, ele-
vated concentrations of total cholesterol, VLDL (very
low density lipoprotein), IDL (intermediate density lipo-
protein), LDL and decreased HDL cholesterol appear
[18]. In this study significantly lower concentrations of
total cholesterol and LDL cholesterol in CKD patients
compared to healthy volunteers were observed. Trigly-
ceride concentrations are usually high in CKD patients
and this disturbance is seen in early stages of CKD and
is present in up to 70% of ESRD patients [18,19]. High-
density lipoprotein (HDL) cholesterol is subnormal in
the majority of patients, which is consistent with the re-
sults of this study. Uraemia causes qualitative changes in
the composition of LDL, increases the number of small,
dense LDL particles and facilitates their oxidation and
glycation. LDL cholesterol in CKD may be normal or
lower; however, the proportion of small dense LDL par-
ticles, which are considered to be highly atherogenic, is
increased [20]. According to studies [18], the profile of
dyslipidaemia is similar to that found in patients with ac-
celerated atherosclerosis. It seems that greater severity
of atherosclerosis in patients with CKD may also be as-
sociated with disorders of calcium-phosphate metabol-
ism. Impaired excretion of phosphate leads to its
increased concentration, to binding with calcium in tis-
sues and to the accumulation of such compound in the
arteries, which increases the risk of heart attack and
stroke [21]. High levels of phosphate usually appear
when the GFR falls below 60 ml/min and worsens with
the deterioration of renal excretory functions. Hyperpho-
sphataemia stimulates parathyroid glands to increased
secretion of parathyroid hormone (PTH), which in turn
increases the release of phosphate from the bone, con-
tributing to further accumulation of phosphate in serum.
High levels of inorganic phosphate in CKD patients ob-
served in this study are in accordance with the results of
other studies.
Progressive left ventricular enlargement seems to be
the most characteristic morphological pattern of dialysis
Table 3 Results of analysis of correlation between concentration of selected proteins and biochemical parameters
Ca2+ Inorganic P CRP HDL LDL TCH TG CRP GFR-MDRD Ca2+ Inorganic P Fe
Osteopontin 0.024 NS 0.009 NS 0.094 NS ABCA1 0.012 NS 0.016 NS 0.127 NS 0.032 NS −0.154 NS
Osteoprotegerin −0.117 NS 0.385 P < 0.0001 0.290 P = 0.001 ABCG1 0.150 NS −0.109 NS 0.052 NS −0.097 NS −0.014 NS
Osteokalcin −0.144 NS 0.192 P = 0.041 0.019 NS MMP-2 −0.079 NS −0.001 NS 0.096 NS 0.125 NS 0.113 NS 0.048 NS 0.095 NS −0.119 NS 0.149 NS
Fetuin A 0.270 P = 0.003 −0.296 P = 0.001 −0.117 NS MMP-9 −0.075 NS −0.060 NS −0.104 NS −0.040 NS 0.167 NS (p = 0.066) −0.162 NS −0.038 NS 0.026 NS −0.067 NS
MGP −0.41 NS −0.005 NS 0.034 NS TIMP-1 −0.062 NS 0.084NS −0.067 NS −0.093 NS 0.007 NS −0.169 NS −0.083 NS 0.105 NS −0.095 NS
Creatinine Urea CRP TIMP-2 −0.019 NS 0.029 NS 0.050 NS 0.128 NS −0.028 NS −0.272 P = 0.007 −0.091NS 0.061 NS −0.223 P = 0.018
Renalase 0.410 0.376 0.073 NS
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diovascular mortality rates in ESRD patients [22,23]. In
this study systolic and diastolic dimensions of the left
ventricle as well as LV mass differed significantly be-
tween CKD patients and controls. These parameters
were much higher in ESRD patients than in patients
with CKD stage I/II According to Zoccali et al. [24], pa-
tients in the highest tertiles of change in LV mass under-
going haemodialysis had a 50% mortality risk and >85%
CV event risk at 3 years. Moreover, another study [25]
demonstrated that a 10% decrease in left ventricle (LV)
mass (∼29 g) was associated in haemodialysis patients
with a 28% decrease in mortality risk from cardiovascu-
lar causes over an almost 5-year follow-up. Numerous
studies have demonstrated that diastolic dysfunction,
which is common in chronic kidney disease (CKD), ac-
counts for 40%-66% of cardiovascular complications
[26]. The proper diagnosis of LV diastolic dysfunction is
very important since it has been demonstrated that it
provides independent, prognostic value for long-term
mortality and cardiovascular death in patients with end-
stage renal disease [27]. Also the study of Iwabuchi et al.
[28] demonstrated that E/E’ ratio is a significant pre-
dictor of cardiovascular events in haemodialysis patients
with preserved LV systolic function and is better than
other echocardiographic parameters. However, in this
study significant differences in indices of diastolic dys-
function (E/A and E/E’) between study group and con-
trols were not observed. This may be due to the fact
that the studied groups were not large.
Lower ejection fraction and frequent mitral and tricus-
pid regurgitation observed in CKD patients in this study
is consistent with the results of other studies [29]. It has
been observed that the calcification process is common
and more severe in the CKD population compared with
healthy people [30]. According to studies, in addition to
arterial wall calcification in patients with CKD valvular
calcification is frequently observed. These changes are
localized mainly within the mitral valve ring and extend
towards valve leaflets [31,32]. It is believed that the se-
verity of vascular and valvular calcification in patients
undergoing haemodialysis correlates with the incidence
of cardiovascular complications and is a predictor of car-
diovascular mortality [31,33]. In this study aortic and
mitral valve calcification was observed, and they were
much more frequent in CKD patients than in healthy
volunteers. In the study of Leskinen et al. [34] combined
prevalence of mitral or aortic valve calcification was 31%
in pre-dialysis patients, 50% in dialysis patients and
12% in controls (p = 0.001). In the Multi-Ethnic Study of
Atherosclerosis in patients with moderate CKD and no
clinical cardiovascular disease, calcification of the aortic
valve and mitral valve was present in 25 and 20% of people
respectively [35]. It is believed that the severity of vascularand valvular calcification in haemodialysis patients cor-
relates with the incidence of cardiovascular complications
and is a predictor of cardiovascular mortality [32,36]. The
contribution of traditional risk factors does not fully ex-
plain the high frequency of cardiovascular disease, and
thus scientists look for new mechanisms involved in its
pathogenesis [37-42]. The coronary artery calcification
score (CACS) may be as much as 5-fold higher in patients
on maintenance haemodialysis than in age-matched non-
CKD patients [43]. Nowadays it seems that the differen-
tiation of vascular smooth muscle cells (VSMCs) into
chondrocytes or osteoblast-like cells is a key element in
vascular/valvular pathogenesis [44]. Many bone-associated pro-
teins, including osteocalcin (OC), matrix γ-carboxyglutamic
acid protein (MGP), osteoprotegerin (OPG), osteopontin
(OPN) and fetuin A, are expressed in atherosclerotic pla-
ques and participate in atherosclerotic calcification. In an
in vitro study, exogenous osteocalcin inhibited the process
of calcification [45]. According to the literature, its con-
centration in patients with CKD is high. Increased serum
concentration of osteocalcin in patients with CKD may be
associated with reduced renal clearance, increased bone
metabolism or a combination of both phenomena [46,47].
In this study, only concentrations of fetuin A (associated
with the presence of massive calcifications of soft tissue
and widespread arterial calcification [48,49]) and osteocal-
cin (which is considered to be the key factor in the devel-
opment of atherosclerosis) significantly differed between
patients with chronic kidney disease and controls. The
concentration of osteocalcin was lowest in patients with
stage I/II CKD and gradually increased to reach its highest
value in patients with stage V/dialysis. According to
Delmas et al. [47], raised levels of circulating osteo-
calcin in patients with mild or moderate renal impairment
reflect enhanced bone metabolism rather than decreased
renal filtration. In this study, fetuin A level decreased sig-
nificantly with the progression of CKD, which is consist-
ent with the results of other studies [50,51]. Schafer et al.
[52] suggested that fetuin A deficiency in haemodialysis
patients may be responsible for the development of calci-
phylaxis, which includes changes in small arterioles. A
low level of fetuin A in these patients is considered an
independent risk factor for increased mortality from car-
diovascular causes [53]. Furthermore, Wang et al. [54]
demonstrated that serum concentration of fetuin A de-
creased as MIA syndrome intensified. However, our study
failed to observe such an association, probably due to the
quite small study group. Also, osteoprotegerin deficiency
leads to vascular calcification since it inhibits osteoclast
differentiation and is a crucial modulator of bone re-
sorption [37,55]. In this study, the concentration of osteo-
protegerin in controls and study groups did not differ
significantly; however, the authors observed its lowest
values in subjects with I/II stage CKD and highest in
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crease of osteoprotegerin levels with increasing renal im-
pairment are consistent with the results of other studies.
The study by Amann K [56] showed that levels of osteo-
protegerin in CKD patients are elevated, which is a de-
fence mechanism against vascular calcification. Bucay
et al. [48] demonstrated that mice lacking the osteoproteg-
erin gene had severe osteoporosis accompanied by rapid
progression of calcification of arteries, while the exogen-
ous administration of OPG inhibited the vascular calcifi-
cation process. On the other hand, it was found that the
expression of OPG in the atheromatous plaque and in vas-
cular smooth muscle cells is very high and it is regulated
by a number of inflammatory cytokines [57]. Other studies
have shown that both the process of vascular calcification
[58] and the aortic calcification index [59] correlated with
serum concentration of OPG in patients on haemodialysis.
It seems that increased levels of OPG in patients with
CKD can affect both the presence of systemic inflam-
mation and local dysfunction of vascular endothelium
[60]. In this study, there are slight differences in osteo-
pontin concentration between groups, however, they did
not reach statistical significance level, probably due to
small study groups.
Because the calcification process is in part associated
with the degradation of elastin, this study examined the
level of metalloproteinases (MMPs) and their inhibi-
tors. Degradation of elastin by matrix metalloproteinases
(MMP-2 and −9) [37,61,62] activates the mitogen-
activated protein kinase (MAPK) signalling pathway and
may further result in the induction of Cbfa1/Runx2 and
sequentially initiate the transformation of VSMCs into
osteoblast-like cells [37,63]. Analysis of results of this
study revealed significantly higher levels of MMP-2 in pa-
tients with chronic kidney disease in comparison to the
control group. Also the study of Musial et al. [33] demon-
strated that concentrations of MMP-2 increased with the
decline of renal function. Similarly, Nagano et al. [64] ob-
served a correlation between serum concentration of
MMP-2 and kidney function parameters and confirmed
that MMP-2 can be an indicator of the severity of athero-
sclerosis in CKD patients. Apart from MMP-2, the role of
MMP-9 in the pathogenesis of vascular changes in athero-
sclerosis has also been established. The study by Chen
et al. [65] revealed increased expression of MMP-2 and
MMP-9 in areas of aorta calcification. Moreover, MMP in-
hibitors decreased calcification of aorta rings from normal
and CKD rats, which may suggest that degradation of the
extracellular matrix is a critical step in the pathogenesis of
arterial calcification in CKD [65]. In this study, significant
differences in concentration of TIMP-2 between CKD pa-
tients and controls and in metalloproteinase inhibitors
TIMP-1 and TIMP-2 and the MMP-2/TIMP-2 ratio be-
tween CKD subjects in various stages were observed. Thestudy of Musial et al. [33] demonstrated that concentra-
tions of TIMP-1 and −2 start to increase in the advanced
stages of CKD, so they are probably a response to the in-
creased activity of matrix metalloproteinases.
A key stage in the atherosclerotic process is the forma-
tion of foam cells from macrophages. Numerous studies
indicate that combined action of transport proteins
ABCA1 and ABCG1 in macrophages are very important
for the anti-atherogenic effect of HDL. ABCA1 plays an
important role in reverse cholesterol transport; its activity
is associated with HDL cholesterol concentration and ath-
erosclerosis. ABCG1 enables transport of phospholipids
and cholesterol from cell membranes to ApoAI-rich HDL
precursors and can act synergistically with ABCA1 to re-
move cholesterol from cells [66]. Both transporters me-
diate macrophage cholesterol efflux, and protect against
the formation of foam cells from macrophages, infiltration
of inflammatory cells, apoptosis and atherosclerosis [67].
In humans, a homozygous variant of ABCA1 present in
Tangier disease is associated with a very low level of HDL
cholesterol, a high concentration of triglycerides, and six
times higher risk of cardiovascular disease [68]. In turn,
the disruption of the ABCG1 gene in mice fed with a
high-fat diet results in a massive accumulation of lipid in
macrophages in various tissues [69]. However, no signifi-
cant differences in ABCA1 and ABCG1 between study
and control groups were found. Increased levels of rena-
lase in CKD patients, observed in this study, are consistent
with the study of Desir et al. [70,71]. Concentration of this
protein was higher in patients with early stages of CKD
than in the control group. Similar observations were made
in the Malyszko et al. [72,73] study, in which the renalase
level was much higher in patients who had undergone
renal transplant than in healthy subjects. Renalase concen-
tration in patients with CKD correlates with increased
plasma norepinephrine levels, systolic blood pressure
and proteinuria, suggesting that this protein plays an
important role in the metabolism of catecholamines,
participates in the development of hypertension and car-
diovascular disorders, and may directly or indirectly con-
tribute to kidney damage [74] and increased mortality of
CKD patients [75,76].
Our study also revealed a correlation between osteocal-
cin level and inorganic P and between osteoprotegerin
and inorganic P and CRP. In patients with CKD, it is well
established that hyperphosphataemia is associated with
the development of vascular calcification [38,44,77-82].
Recent studies have demonstrated that high extracellular
phosphate levels induce the transformation of VSMCs
into osteoblast-like cells, which suggests that vascular cal-
cification is an active process. Moreover, elevated extracel-
lular phosphate levels are associated with the increase in
bone-associated proteins such as osteocalcin and osteo-
pontin [38,78]. Fetuin A correlated well with the level of
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positive correlation between serum fetuin A and calcium
[80]. In this study, a relationship between the concentra-
tion of renalase and the kidney injury markers creatinine
and urea was noted. In the study by Malyszko et al. [72],
renalase levels in patients after kidney transplantation
also correlated with plasma creatinine concentration and
MDRD eGFR values.
Limitations
Our study has some limitations. The number of partici-
pants included to the study is relatively small (139 pa-
tients with CKD and 45 healthy volunteers). Study and
control groups differ in age due to the fact that it is diffi-
cult to find healthy people aged 60–70 years to match
study group. There are also differences in other demo-
graphic data such as sex, diabetes mellitus and hyperten-
sion between groups.
Conclusions
In conclusion, we showed that significantly decreased
levels of fetuin A and increased concentration of osteo-
calcin were present in all patients with chronic kidney
disease. Moreover, MMP-2 and TIMP-2 concentrations
were much higher in patients with chronic kidney dis-
ease, suggesting that these factors may be involved in
the pathogenesis of CAD in patients with CKD. Lack of
significant differences in parameters associated with the
transport of cholesterol may mean that commonly mea-
sured cholesterol level does not play the important role
in the CV risk stratification in CKD patients. Moreover,
according to literature, in uremic conditions HDL parti-
cles may lose their protective properties and also become
atherogenic. The level of renalase was significantly higher
in patients with CKD than in controls and it increased
with the deterioration of renal function. The results sug-
gest that that valvular calcifications may constitute a
marker for atherosclerosis.Competing interest
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